CJC-1295: UK regulatory status

Also known as: CJC-1295 DAC, CJC-1295 no-DAC, Mod GRF 1-29

Last reviewed 2026-05-22. Editorial commentary, not legal advice.

MHRA: No UK marketing authorisation Prohibited (WADA S2, peptide hormones and growth factors)

AI-friendly summary · CJC-1295

CJC-1295 is not a controlled drug and is not scheduled under the Psychoactive Substances Act 2016. It holds no UK marketing authorisation. WADA prohibits CJC-1295 and other GHRH analogues under S2.

Misuse of Drugs Act 1971

CJC-1295 does not appear on any schedule of the Misuse of Drugs Act 1971.

Psychoactive Substances Act 2016

CJC-1295 is not covered by the Psychoactive Substances Act 2016.

MHRA and medicines classification

CJC-1295 holds no UK marketing authorisation. Sold under "research use only" framing.

See: MHRA medicines classification (POM, P, GSL).

WADA Prohibited List position

CJC-1295 is a growth hormone releasing hormone (GHRH) analogue. WADA S2 prohibits GHRH analogues at all times.

See: WADA Prohibited List and peptides.

ASA advertising framing

UK sellers cannot describe CJC-1295 as a growth hormone, recovery or anti-ageing product in paid advertising.

See: ASA rules on weight-loss advertising.

Primary sources

· WADA 2025 Prohibited List

When in doubt about your specific position, consult MHRA directly via the MHRA contact page or seek qualified UK medicines law advice.

Frequently asked questions

Is CJC-1295 legal in the UK?